Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$31.0 - $55.72 $12.4 Million - $22.3 Million
-400,000 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$37.09 - $48.97 $741,800 - $979,400
20,000 Added 5.26%
400,000 $14.8 Million
Q3 2020

Nov 13, 2020

SELL
$40.47 - $45.5 $809,400 - $910,000
-20,000 Reduced 5.0%
380,000 $15.6 Million
Q2 2020

Aug 14, 2020

SELL
$32.57 - $42.83 $6.51 Million - $8.57 Million
-200,000 Reduced 33.33%
400,000 $16.2 Million
Q1 2020

May 14, 2020

BUY
$23.3 - $45.96 $4.66 Million - $9.19 Million
200,000 Added 50.0%
600,000 $20.9 Million
Q4 2019

Feb 13, 2020

BUY
$34.58 - $48.06 $7.61 Million - $10.6 Million
220,000 Added 122.22%
400,000 $17.2 Million
Q2 2019

Aug 09, 2019

SELL
$35.13 - $55.53 $702,600 - $1.11 Million
-20,000 Reduced 10.0%
180,000 $8.13 Million
Q1 2019

May 10, 2019

SELL
$42.83 - $59.91 $4.28 Million - $5.99 Million
-100,000 Reduced 33.33%
200,000 $10.9 Million
Q4 2018

Feb 11, 2019

BUY
$37.97 - $60.16 $1.9 Million - $3.01 Million
50,000 Added 20.0%
300,000 $13.9 Million
Q1 2018

May 10, 2018

BUY
$45.35 - $61.65 $11.3 Million - $15.4 Million
250,000 New
250,000 $11.6 Million
Q4 2017

Feb 09, 2018

SELL
$41.95 - $60.1 $2.1 Million - $3.01 Million
-50,000 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$33.4 - $53.9 $1.67 Million - $2.7 Million
50,000
50,000 $2.69 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.